NCT07285213

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-12-10Est. Completion: 2027-04-20

Enrollment target: 230 participants

Locations

Research Site, Phoenix, Arizona, United States
Research Site, Chula Vista, California, United States
Research Site, Sacramento, California, United States
Research Site, Torrance, California, United States
Research Site, Hamden, Connecticut, United States
Research Site, Gainesville, Florida, United States
Research Site, Hialeah, Florida, United States
Research Site, Homestead, Florida, United States
Research Site, Jacksonville, Florida, United States
Research Site, Miami Lakes, Florida, United States
Research Site, Miramar, Florida, United States
Research Site, Port Orange, Florida, United States
Research Site, Tamarac, Florida, United States
Research Site, Tampa, Florida, United States
Research Site, Athens, Georgia, United States
Research Site, Atlanta, Georgia, United States
Research Site, Idaho Falls, Idaho, United States
Research Site, Burr Ridge, Illinois, United States

Other microbiome trials you might be interested in

Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationPhase 2Recruiting

Acute Leukemia in RemissionMyelodysplastic SyndromesMyeloproliferative SyndromeHodgkin LymphomaLymphoma, Non-HodgkinMyelomaChronic Lymphocytic Leukemia

The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic h…

Amiens, FranceEst. completion May 2030

View Trial →

AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative ColitisRecruiting

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.